Clinical Trials Logo

Filter by:
NCT ID: NCT04885946 Active, not recruiting - Clinical trials for Clostridium Difficile Infection

Fecal Microbiota Transplantation for Early Clostridioides Difficile Infection

EarlyFMT
Start date: June 2, 2021
Phase: N/A
Study type: Interventional

Clostridioides difficile (CD) infection (CDI) is a global health threat with an urgent need for new treatment strategies. Faecal microbiota transplantation (FMT) is effective for recurrent Clostridioides difficile infection (CDI), and is currently recommended for multiple (three or more), recurrent CDI infections. The role of FMT earlier in the treatment hierarchy of CDI remains to be determined. In this randomized, double-blinded, placebo-controlled clinical trial, we compare FMT with placebo following standard antibiotic treatment for first or second Clostridioides difficile infection.

NCT ID: NCT04876963 Active, not recruiting - Clinical trials for Cardiovascular Diseases

HOLT-ED: Holter-monitoring in End-stage Renal Disease

Start date: September 1, 2021
Phase:
Study type: Observational [Patient Registry]

The main objective of this prospective cohort study is to assess arrhythmia burden and glycemic variability in a multicenter cohort of patients with end-stage renal disease using a sufficient observation period in order to identify arrhythmia burden and type and characterize associations with patient characteristics and dialysis treatment, glycemic variability and subsequent risk of adverse outcomes.

NCT ID: NCT04876092 Active, not recruiting - Clinical trials for Lymphoma, Non-Hodgkin

A Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in B-cell NHL and CLL

Start date: July 28, 2021
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the safety and recommended Phase 2 dose (RP2D) of JNJ-67856633 and ibrutinib in combination in participants with B cell non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL).

NCT ID: NCT04865770 Active, not recruiting - Clinical trials for Diabetes Mellitus, Type 2

A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial)

REMODEL
Start date: April 28, 2021
Phase: Phase 3
Study type: Interventional

We are doing this study to learn more about how semaglutide may help fight chronic kidney disease in people with type 2 diabetes. We are doing this by looking into how semaglutide works in the kidneys. Participants will either get semaglutide or placebo (a 'dummy' medicine) - which treatment participants get is decided by chance. Semaglutide is a medicine doctors can prescribe in some countries for the treatment of type 2 diabetes. Participants will get the study medicine in a pen. Participants will use the pen to inject the medicine into the skin once a week. The study will last for about 1 year. Participants will have 11 visits to the clinic, and 2 phone visits. Some of the visits could be in different locations. Study staff will take blood samples at most of these visits. At 9 visits, participants will be asked to bring a sample of their first morning urine. At 4 of the visits participants will have to bring urine that they have collected over the last 24 hours. The study includes magnetic resonance imaging (MRI) scans of participants' kidneys which is a test that shows a detailed picture of organs and other parts inside the body. The scan will last for 30 minutes, and is free of radiation.

NCT ID: NCT04864392 Active, not recruiting - Osteoarthritis Clinical Trials

Study of Efficacy, Safety, and Tolerability of LNA043 in Patients With Knee Osteoarthritis

ONWARDS
Start date: May 31, 2021
Phase: Phase 2
Study type: Interventional

The study will determine the optimal dosing regimen of LNA043 in patients with knee osteoarthritis (OA).

NCT ID: NCT04860830 Active, not recruiting - Schizophrenia Clinical Trials

CONNEX-3: A Study to Test Whether Iclepertin Improves Learning and Memory in People With Schizophrenia

Start date: June 18, 2021
Phase: Phase 3
Study type: Interventional

This study is open to adults with schizophrenia. Schizophrenia can affect the way a person thinks, their memory and their mental functioning. Examples include struggling to remember things, or to read a book or pay attention to a movie. Some people have difficulty calculating the right change or planning a trip so that they arrive on time. The purpose of this study is to find out whether a medicine called iclepertin improves learning and memory in people with schizophrenia. Participants are put into two groups randomly, which means by chance. One group takes iclepertin tablets and the other group takes placebo tablets. Placebo tablets look like iclepertin tablets but do not contain any medicine. Participants take a tablet once a day for 26 weeks. In addition, all participants take their normal medication for schizophrenia. During this time, doctors regularly test learning and memory of the participants by use of questionnaires, interviews, and computer tests. The results of the mental ability tests are compared between the groups. Participants are in the study for about 8 months and visit the study site about 14 times. During this time, doctors regularly check participants' health and take note of any unwanted effects.

NCT ID: NCT04851964 Active, not recruiting - Clinical trials for Chronic Rhinosinusitis With Nasal Polyps

Efficacy and Safety of Tezepelumab in Participants With Severe Chronic Rhinosinusitis With Nasal Polyposis

WAYPOINT
Start date: April 22, 2021
Phase: Phase 3
Study type: Interventional

A Multicentre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Participants with Severe Chronic Rhinosinusitis with Nasal Polyposis

NCT ID: NCT04851717 Active, not recruiting - Pediatric ALL Clinical Trials

Investigation of Remimazolam in Children Undergoing Sedation for Medical Procedures

Start date: November 15, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

To assess the efficacy of intravenous remimazolam in inducing and maintaining suitable sedation levels for paediatric patients undergoing diagnostic and/or therapeutic procedures

NCT ID: NCT04848545 Active, not recruiting - Testicular Cancer Clinical Trials

Endocrine Disrupting Chemical Exposure and Testicular Cancer

DISRUPT
Start date: June 1, 2020
Phase:
Study type: Observational

DISRUPT is a Danish nested case-control study that is currently being conducted to explore the impact of prenatal exposure to endocrine disrupting chemicals on testicular cancer risk (including histological sub-groups) with emphasis on the analysis of exposure mixtures. Pregnant mothers provided serum and amniotic fluid at recruitment up to 50 years ago. By registry linkage within highly reliable national population and disease registries cancer cases and matched controls will be identified. Levels of EDCs including DDT, DDE and other organochlorine pesticides, PCBs, PBDEs, PFAS, phthalates and triclosan will be quantified in cases whose sons develop testicular cancer during 40 year follow up and compared to controls.

NCT ID: NCT04842149 Active, not recruiting - Crohn Disease Clinical Trials

The Effects of Bifidobacterium Breve Bif195 for Small Intestinal Crohn's Disease

Start date: May 21, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to investigate if the probiotic Bifidobacterium breve Bif195 (Bif195) will result in improvement in clinical outcome in patients with small intestinal Crohn's disease.